Belite Bio, Inc
BLTE
Rankning i aktier
#2968
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Aktiekurs
$154.77
Marknadsvärde
$6.23B
Förändring (1 dag)
5.04%
Förändring (1 år)
71.26%
Land
US
Handel Belite Bio, Inc (BLTE)
Kategori
Healthcare
Historik för aktiesplit för Belite Bio, Inc (BLTE)
Aktien Belite Bio, Inc (symbol: BLTE) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 20, 2026.
En BLTE-aktie köpt före Oct 20, 2026 motsvarar nu 0 BLTE-aktier.
Den senaste spliten skedde den Oct 20, 2026.
En BLTE-aktie köpt före Oct 20, 2026 motsvarar nu 0 BLTE-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
